×
Customize
?
Start
Cancer Types
Quick Links
Award Programs
Cure Media Group, LLC.
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 800-210-2873
Copyright © 2018
CURE Media Group.
All rights reserved.
Cure Media Group, LLC. All Rights Reserved.
CURE does not provide medical, diagnostic, or treatment advice.
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 800-210-2873
Copyright © 2018
CURE Media Group.
All rights reserved.
Cure Media Group, LLC. All Rights Reserved.
CURE does not provide medical, diagnostic, or treatment advice.
Immunotherapy
Brielle Urciuoli
Promising results from a recent trial are laying the groundwork for the first change in frontline small cell lung cancer in two decades.
Katie Kosko
The immunotherapy agent Keytruda is showing promise for treating non-muscle invasive bladder cancer, according to a recent study.
Jason Harris
Immunotherapy pioneers James P. Allison, Ph.D., and Tasuku Honjo, M.D., Ph.D., have won the 2018 Nobel Prize in Physiology or Medicine for their research that eventually led to the use of immune checkpoint inhibitors to treat cancer.
Angelica Welch
After chemotherapy, immunotherapy has become the standard treatment for bladder cancer. Will it ever play a bigger role?
Brielle Urciuoli
While there is currently no definitive way to predict who will respond and who will not, researchers at Brighton and Sussex Medical School in the United Kingdom are working on a blood test that could identify about half of those who may not.
Brielle Urciuoli
In recent years, immunotherapy has been falling flat in the brain cancer field, but recent research may change that.
Kristie L. Kahl
Patients who receive anti-PD-1 therapies may experience delayed cutaneous side effects like lesions, eczema or psoriasis, even after treatment has ended.
Kristie L. Kahl
In this week’s episode of CURE® Talks Cancer, we delve into immunotherapy breakthroughs and how a new series of patient summits can help individuals learn more.
Jessica Skarzynski
Take a look at the top five CURE stories of July 2018 in this video.
Jessica Skarzynski
Because little is known about the effect of patients' sex on the efficacy of immune checkpoint inhibitors as cancer treatments, the researchers performed a systematic review and meta-analysis to determine the heterogeneity of immune checkpoint inhibitor efficacy between men and women.